Oric Pharmaceuticals Inc. (ORIC)
ORIC trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | ORIC on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2020 |
| SEC CIK | 0001796280 |
Financials
Not reported in SEC XBRL data.
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-08-03 |
| Cash and burn | $37.5M cash; operating cash flow -$27.9M a quarter. | Report 2026-06-30 |
| Shares outstanding | 103,652,656 (2026-07-27); 97,122,987 a year earlier; 54,532,614 three years earlier. | Cover page 2026-07-27 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the market | Latest 2026-02-23 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | KPMG LLP, San Diego, California, United States | PCAOB Form AP 2026-03-18 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $3.8M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q2 2026 2026-06-30 | Not filed | -$41.5M | -$31.6M | $37.5M | No debt tags | Needs four quarters | 10-Q 2026-08-03 |
| Q1 2026 2026-03-31 | Not filed | -$35.8M | -$32.4M | $56.4M | No debt tags | Needs four quarters | 10-Q 2026-05-04 |
| Q4 2025 2025-12-31 | Not filed | -$30.5M | -$22.5M | $45.7M | No debt tags | Needs four quarters | 10-K 2026-02-23 |
| Q3 2025 2025-09-30 | Not filed | -$32.6M | -$25.1M | $49.7M | No debt tags | Needs four quarters | 10-Q 2025-11-13 |
| Q2 2025 2025-06-30 | Not filed | -$36.4M | -$30.8M | $75.9M | No debt tags | Needs four quarters | 10-Q 2026-08-03 |
| Q1 2025 2025-03-31 | Not filed | -$30.0M | -$32.5M | $49.3M | No debt tags | Needs four quarters | 10-Q 2026-05-04 |
| Q4 2024 2024-12-31 | Not filed | -$36.3M | -$28.1M | $59.4M | No debt tags | Needs four quarters | 10-K 2026-02-23 |
| Q3 2024 2024-09-30 | Not filed | -$34.6M | -$28.8M | $44.2M | No debt tags | Needs four quarters | 10-Q 2025-11-13 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
The SEC filing list did not load in time for this page. It is on SEC EDGAR and in the full dossier.
Price moves
| Window | Return |
|---|---|
| 1 week | -10.9% |
| 1 month | -30.5% |
| 3 months | -42.7% |
| Year to date | -3.9% |
| 1 year | -35.5% |
| From 52-week high | -46.3% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| LXRX | Lexicon Pharmaceuticals Inc. | $1.75 | -2.23% | $779.2M |
| IVA | Inventiva S.A. American Depository Shares | $3.32 | -9.78% | $784.5M |
| ARDX | Ardelyx Inc. | $3.07 | -0.65% | $771.7M |
| COLL | Collegium Pharmaceutical Inc. | $25.43 | +0.43% | $790.2M |
| OBX | Obsidian Therapeutics Inc. | $12.36 | -1.59% | $763.5M |
| IRWD | Ironwood Pharmaceuticals Inc. | $4.85 | +0.41% | $802.9M |
| SNDX | Syndax Pharmaceuticals Inc. | $9.13 | -3.39% | $821.6M |
| RIGL | Rigel Pharmaceuticals Inc. | $43.73 | -1.64% | $823.4M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier